Wyeth unveils data from Prevenar 13 vaccine trial
COLLEGEVILLE, Pa. A drug maker developing a vaccine to prevent pneumococcal disease in children said new clinical data could protect against the most common serotypes of the disease.
Wyeth announced Thursday that data from phase 3 trials in Europe showed that Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, 13-valent [adsorbed]) could protect against the 13 most prevalent serotypes associated with the disease, the leading cause of vaccine-preventable death in children younger than 5.
Data from the trials were presented at the 27th annual meeting of the European Society for Pediatric Infectious Diseases. The trials took place in France, Italy, Poland, Spain and the United Kingdom
“Our investigational vaccine, Prevenar 13, builds on the scientific foundation of Prevenar and is designed to provide more comprehensive protection against pneumococcal disease,” Wyeth Pharmaceuticals EVP vaccines research and development Emilio Emini said in a statement. “These new data indicate that Prevenar 13 has the potential to provide direct coverage of the 13 most common disease-causing serotypes, including 3, 6A and 19A, which have been increasing in prevalence in many regions around the world.
The vaccine is designed to protect against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.